Skip to main content

3 Result(s)

within Isabella Haberbosch Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

    Nora Liebers, Tobias Roider, Jan-Paul Bohn, Isabella Haberbosch… in Leukemia (2020)

  2. Article

    Open Access

    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

    Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to...

    Afsar Ali Mian, Isabella Haberbosch, Hazem Khamaisie, Abed Agbarya… in Annals of Hematology (2021)

    Download PDF (1192 KB) View Article

  3. Article

    Open Access

    High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

    Plasma cell disorders are clonal outgrowths of pre-malignant or malignant plasma cells, characterized by extensive chromosomal aberrations. Centrosome abnormalities are a major driver of chromosomal instabilit...

    Sebastian Köhrer, Tobias Dittrich, Martin Schorb, Niels Weinhold… in Leukemia (2023)

    Download PDF (2333 KB) View Article